Comparison of pretransplantation prediction models for nonrelapse mortality in patients with myelofibrosis undergoing allogeneic stem cell transplantation

A retrospective study of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), augmented HCT-CI (aHCT-CI), and Endothelial Activation and Stress Index (EASIX) found that EASIX was not a useful predictor of nonrelapse mortality (NRM) in patients with myelofibrosis undergoing allogeneic stem cell transplantation (alloSCT). An increasing log2-EASIX score quartile was not associated with 3-year NRM (19.0% vs. 10.1% vs. 25% vs. 14.3%; P = .59), nor with 3-year overall survival (3-year OS rate, 66.7% vs. 80.4% vs. 64.6% vs. 76.2%; P = .57). Both the HCT-CI and the aHCT-CI demonstrated accuracy in predicting NRM and OS in this patient population.